Teleflex Incorporated (NYSE: TFX) — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also provides unaudited fourth-quarter results. Amounts below are U.S. dollars; financial figures are in millions unless noted.
Business context
Teleflex is a global medical-technology company, with approximately 95% of revenue from single-use medical devices. It reports four segments: Americas, EMEA, Asia and OEM. Its products serve hospitals and healthcare providers, other medical-device manufacturers, and home care. COVID-19 reduced elective procedures, weighing on several product lines, while demand rose for respiratory and vascular-access products.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Net revenue | $2,537.2 | $2,595.4 |
| Gross profit / gross margin | $1,324.9 / 52.2% | $1,409.0 / 54.3% |
| Income before interest, debt extinguishment and taxes | $423.1 | $427.3 |
| Income from continuing operations | $335.8 | $462.0 |
| Net income | $335.3 | $461.5 |
| Diluted EPS from continuing operations | $7.10 | $9.81 |
| Operating cash flow from continuing operations | $437.1 | $437.1 |
| Capital expenditures / free cash flow (non-GAAP) | $90.7 / $346.4 | $102.7 / $334.4 |
Revenue declined 2.2%, primarily due to a $108.2 million net decrease in existing-product sales volumes, largely related to the pandemic; HPC contributed $27.1 million after acquisition. Lower volume, higher manufacturing costs and unfavorable currency movements reduced gross margin by 210 basis points. SG&A fell $108.2 million, including a $92.1 million benefit from reductions in the estimated fair value of contingent consideration, as well as lower selling, marketing and performance-related costs. The 2020 effective tax rate was 6.1%, versus negative 35.9% in 2019; the 2019 rate included a $129 million discrete tax benefit from a non-U.S. legal-entity restructuring.
At year-end, cash and cash equivalents were $375.9 million, total debt was $2,498.0 million and net debt was $2,122.1 million. Net debt to total capital increased to 38.9% from 35.2%. Current assets were $1,422.4 million and current liabilities $540.0 million. The company had $350 million drawn on its $1 billion revolving facility and $75 million outstanding under its receivables securitization facility. Management stated that operating cash flow, available cash and borrowing capacity should fund requirements and debt obligations for the next 12 months and foreseeable future. About $310.4 million of cash was held at non-U.S. subsidiaries.
Investing activities used $837.8 million, including $767.8 million of net payments for acquired businesses and $90.7 million of capital expenditures. Financing activities provided $455.2 million, reflecting a net increase in borrowings of $575 million, partly offset by contingent-consideration and dividend payments. The annual dividend remained $1.36 per share.
Comparisons and fourth-quarter results
Annual revenue decreased from 2019, while continuing-operations income fell 27.3% and diluted EPS declined 27.6%. The earnings comparison is affected by the 2019 tax benefit and the 2020 contingent-consideration fair-value benefit. Operating cash flow was essentially unchanged year over year. By segment, Americas revenue fell 1.8%, EMEA 0.5%, Asia 9.3%, and OEM 0.2%; segment operating profit rose 25.5% in Americas but declined in EMEA, Asia and OEM.
Fourth-quarter 2020 revenue was $711.2 million, up from $681.0 million in Q4 2019. Fourth-quarter income from continuing operations was $76.6 million versus $107.8 million, and diluted EPS from continuing operations was $1.62 versus $2.28.
Outlook, risks and unusual items
- COVID-19: Management said the pandemic was expected to continue negatively affecting revenue and operations in the near term. Recovery varied by region and product category; renewed procedure deferrals, manufacturing inefficiencies, workforce absences and supply or shipping delays remained risks. The filing gives no numerical revenue or earnings guidance.
- Acquisitions and restructuring: Teleflex acquired HPC for an initial $260 million and Z-Medica for an initial $500 million, with up to $25 million of additional Z-Medica milestone consideration. A 2020 workforce-reduction plan was substantially completed and is expected to yield $12 million in annual pretax savings. Across ongoing restructuring programs and the OEM initiative, estimated total annual pretax savings are $86–$97 million when fully implemented; timing and realization remain uncertain.
- Contingencies and investigations: The DOJ is investigating NeoTract under the civil False Claims Act, including rebate programs and broader operations; the company said it cannot reasonably estimate any potential liability. Chinese authorities may impose a penalty related to tariff classifications; Teleflex recorded $3 million, the low end of its estimated $3–$20.3 million range. In February 2021, former Essential Medical shareholders sued for $66.9 million plus interest over acquisition milestone payments; Teleflex disputed the claims and intends to defend itself.
- Other risks: Significant indebtedness and debt covenants, foreign-exchange exposure, medical-device regulation (including the EU MDR), product liability and recalls, reimbursement and pricing pressure, supplier and sterilization capacity, cybersecurity, and execution of acquisitions and restructuring could adversely affect results. The filing also describes ethylene-oxide sterilization risks and possible environmental liabilities.
- Unusual operating item: Teleflex recorded $21.4 million of impairment charges, primarily for abandoning Percuvance product-line intellectual property and other assets. It reported no goodwill impairment for 2020.
Most important facts for investors to verify
- Whether elective-procedure demand and affected product categories recover, and whether higher respiratory and vascular-access demand persists.
- How much of 2020 earnings benefited from the $92.1 million contingent-consideration fair-value reduction, and the basis for future contingent payments.
- Acquisition integration, purchase-accounting assumptions and realization of the stated restructuring savings.
- Developments and potential financial exposure in the DOJ, China tariff and Essential Medical matters.
- Debt maturities, covenant headroom, cash accessibility and sensitivity to interest rates and currency movements.